{"cik":2096997,"taxonomy":"us-gaap","tag":"AllocatedShareBasedCompensationExpense","label":"Share-based Payment Arrangement, Expense","description":"Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.","entityName":"Kailera Therapeutics, Inc.","units":{"USD":[{"start":"2025-01-01","end":"2025-03-31","val":1523000,"accn":"0001193125-26-239417","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-26","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":3154000,"accn":"0001193125-26-346958","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2025-04-01","end":"2025-06-30","val":1631000,"accn":"0001193125-26-346958","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2025Q2"},{"start":"2026-01-01","end":"2026-03-31","val":3939000,"accn":"0001193125-26-239417","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-26","frame":"CY2026Q1"},{"start":"2026-01-01","end":"2026-06-30","val":12283000,"accn":"0001193125-26-346958","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2026-04-01","end":"2026-06-30","val":8344000,"accn":"0001193125-26-346958","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2026Q2"}]}}